Yahoo
NasdaqGS - Nasdaq Real Time Price USD

Denali Therapeutics Inc. (DNLI)

18.30 -0.42 (-2.24%)
At close: May 1 at 4:00:01 PM EDT
18.22 -0.08 (-0.44%)
After hours: May 1 at 7:42:42 PM EDT
Trade DNLI on Coinbase
Chart Range Bar
Loading chart for DNLI
  • Previous Close 18.72
  • Open 18.70
  • Bid 18.24 x 100
  • Ask 18.36 x 100
  • Day's Range 18.23 - 18.81
  • 52 Week Range 12.58 - 23.77
  • Volume 1,495,543
  • Avg. Volume 1,695,455
  • Market Cap (intraday) 2.904B
  • Beta (5Y Monthly) 1.10
  • PE Ratio (TTM) --
  • EPS (TTM) -2.97
  • Earnings Date (est.) May 11, 2026
  • Forward Dividend & Yield --
  • Ex-Dividend Date --
  • 1y Target Est 35.64

Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutics to treat neurodegenerative and lysosomal storage diseases. The company develops Eclitasertib (SAR443122/DNL758) RIPK1 inhibitor program for peripheral inflammatory diseases; BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; TAK-594/DNL593 program for frontotemporal dementia-granulin; DNL126 program for MPS IIIA (Sanfilippo Syndrome A); and DNL310 Tividenofusp alfa, an enzyme replacement therapy program for MPS II (Hunter Syndrome). Its Enzyme TransportVehicle (TV) programs include DNL952 for the treatment of Pompe disease; DNL111 for Parkinson's and Gaucher diseases; and DNL622 for Hurler syndrome (MPS I). The company's OTV programs also comprise DNL628 targeting tau for Alzheimer's disease; and DNL422 targeting alpha synuclein for Parkinson's disease, as well as antibody TV program includes DNL921 targeting Abeta for treating Alzheimer's disease. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.

www.denalitherapeutics.com

503

Full Time Employees

December 31

Fiscal Year Ends

Healthcare

Sector

Biotechnology

Industry

Performance Overview: DNLI

Trailing total returns as of 5/1/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC) .

YTD Return

DNLI
10.84%
S&P 500 (^GSPC)
5.62%

1-Year Return

DNLI
13.95%
S&P 500 (^GSPC)
29.01%

3-Year Return

DNLI
29.07%
S&P 500 (^GSPC)
73.47%

5-Year Return

DNLI
69.72%
S&P 500 (^GSPC)
72.92%

Earnings Trends: DNLI

View More

Earnings Per Share

GAAP
Normalized
GAAP
Normalized

Revenue vs. Earnings

Annual
Quarterly
Annual
Quarterly
Q4 FY25
Revenue --
Earnings -128.55M

Q1

FY25

Q2

FY25

Q3

FY25

Q4

FY25

-100M
-50M
0

Analyst Insights: DNLI

View More

Analyst Price Targets

25.00
35.64 Average
18.30 Current
42.00 High

Analyst Recommendations

  • Strong Buy
  • Buy
  • Hold
  • Underperform
  • Sell

Latest Rating

Date 4/22/2026
Analyst Leerink Partners
Rating Action Maintains
Rating Outperform
Price Action Lowers
Price Target 40 -> 35

Statistics: DNLI

View More

Valuation Measures

Annual
As of 5/1/2026
  • Market Cap

    2.90B

  • Enterprise Value

    2.07B

  • Trailing P/E

    --

  • Forward P/E

    --

  • PEG Ratio (5yr expected)

    --

  • Price/Sales (ttm)

    --

  • Price/Book (mrq)

    2.86

  • Enterprise Value/Revenue

    --

  • Enterprise Value/EBITDA

    --

Financial Highlights

Profitability and Income Statement

  • Profit Margin

    0.00%

  • Return on Assets (ttm)

    -27.56%

  • Return on Equity (ttm)

    -45.69%

  • Revenue (ttm)

    --

  • Net Income Avi to Common (ttm)

    -512.54M

  • Diluted EPS (ttm)

    -2.97

Balance Sheet and Cash Flow

  • Total Cash (mrq)

    867.88M

  • Total Debt/Equity (mrq)

    4.17%

  • Levered Free Cash Flow (ttm)

    -244.19M

Compare To: DNLI

Select to analyze similar companies using key performance metrics; select up to 4 stocks.

Company Insights: DNLI

Fair Value

18.30 Current

Dividend Score

0 Low
Sector Avg.
100 High

Hiring Score

0 Low
Sector Avg.
100 High

Insider Sentiment Score

0 Low
Sector Avg.
100 High

Research Reports: DNLI

View More
  • Daily – Vickers Top Buyers & Sellers for 01/12/2026

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Buyers & Sellers for 01/09/2026

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

  • Daily – Vickers Top Buyers & Sellers for 07/28/2022

    The Vickers Top Buyers & Sellers is a daily report that identifies the five companies the largest insider purchase transactions based on the dollar value of the transactions as well as the five companies the largest insider sales transactions based on the dollar value of the transactions.

People Also Watch

Mobilize your Website
View Site in Mobile | Classic
Share by: